Type of Adverse Event | ETN, n = 71 | ETN + MTX, n = 76 | p |
---|---|---|---|
Blood and lymphatic system disorders | 2 | 0 | 0.232 |
Cardiac disorders | 0 | 1 (1) | 1.000 |
Eye disorders | 1 | 2 | 1.000 |
Gastrointestinal disorders | 7 | 5 | 0.554 |
General disorders and administration site conditions | 15 | 7 | 0.063 |
Hepatobiliary disorders | 1 | 5 | 0.211 |
Infections and infestations | 19 | 21 (2) | 1.000 |
Injury, poisoning, procedural complications | 3 (2) | 5 (3) | 0.720 |
Metabolism and nutrition disorders | 1 | 2 | 1.000 |
Musculoskeletal and connective tissue disorders | 2 | 0 | 0.232 |
Neoplasms benign, malignant, unspecified | 0 | 1 (1) | 1.000 |
Nervous system disorders | 2 | 4 (1) | 0.682 |
Psychiatric disorders | 3 | 3 | 1.000 |
Renal and urinary disorders | 0 | 1 | 1.000 |
Reproductive system and breast disorders | 0 | 1 | 1.000 |
Respiratory, thoracic, mediastinal disorders | 3 | 2 | 0.673 |
Skin and subcutaneous tissue disorders | 11 | 5 | 0.112 |
Vascular disorders | 1 | 0 | 0.483 |
Serious adverse events | 2 | 7 | 0.168 |
ETN: etanercept; MTX: methotrexate.